IVF

Femasys Expands Commercial Management Team with Addition of Experienced New Hires

Retrieved on: 
火曜日, 5月 7, 2024
FDA, Episcopal conference, American College, Woman, Infertility, Insemination, Health, ICSI, IVF, ACOG, Booth, IUI

With the addition of new team members to its commercial team in key strategic geographical locations, Femasys is poised to fully initiate its strategic initiatives and execute on its delivery of innovative, accessible options to impact women’s healthcare.

Key Points: 
  • With the addition of new team members to its commercial team in key strategic geographical locations, Femasys is poised to fully initiate its strategic initiatives and execute on its delivery of innovative, accessible options to impact women’s healthcare.
  • The newly appointed team brings together seasoned professionals with a wealth of commercial experience across various sectors of the healthcare industry.
  • Their collective expertise plays a pivotal role in driving Femasys' commercial efforts forward to realize the Company’s strategic vision, with initial emphasis on the Company’s infertility portfolio, led by the FemaSeed® product.
  • The 2024 ACOG meeting presents an ideal opportunity for Femasys to showcase the strength of its initial commercial team and its commitment to shaping the future of women's healthcare.

Gameto Announces New Data Demonstrating Clinical-Grade Manufacturing of In Vitro Maturation Solution for Fertility Care

Retrieved on: 
水曜日, 5月 8, 2024
FDA, Ovary, Safety, Cell, Infertility, Health, Research, Female, IVF, Patient, IPSC, IVM, GMP, Biotechnology, Medical device

NEW YORK, May 8, 2024 /PRNewswire/ -- Gameto, a female-led biotechnology company with a mission to redefine women's healthcare, today announced new research outlining the cellular engineering and manufacturing techniques underlying Fertilo, their novel investigational in vitro maturation (IVM) solution containing engineered ovarian support cells (OSCs) to mature eggs outside of the body. These data underscore that Gameto's quality by design strategic product development supports the manufacturing of OSC-IVM for clinical and commercial use.

Key Points: 
  • These data underscore that Gameto's quality by design strategic product development supports the manufacturing of OSC-IVM for clinical and commercial use.
  • "We are effectively creating an active cell therapy in a dish, which differs significantly from the media solutions that are currently used for in vitro maturation.
  • These data suggest the applications of this technology could expand beyond OSC-IVM and be used to address additional women's health and fertility issues as well."
  • For more information about Gameto and how the company is redefining women's healthcare, visit gametogen.com.

Olive Fertility Centre Victoria Welcomes New Fertility Specialist Dr. Riki Dayan

Retrieved on: 
月曜日, 5月 6, 2024
Olive, Education, Physician, University, Regius Professor, UBC, Air pollution, Pregnancy, McMaster University, Fertility, Research, Gynaecology, IVF, Family, Patient, Mindfulness, Surgeon, Multimedia, Meditation, Royal college, Medical device

VICTORIA, BC, May 6, 2024 /PRNewswire-PRWeb/ -- Olive Fertility Centre is pleased to announce that Dr. Riki Dayan MD FRCSC has joined the Olive Fertility Victoria Team. "We are delighted to welcome Dr. Dayan to Olive Fertility," says Olive co-director Dr. Niamh Talon. "With her expertise in fertility, her dedication to education and her focus on whole person, patient-centred care, Dr. Dayan is an invaluable addition to the Olive Team."

Key Points: 
  • Olive Fertility Centre is pleased to announce that Dr. Riki Dayan MD FRCSC has joined the Olive Fertility Victoria Team.
  • VICTORIA, BC, May 6, 2024 /PRNewswire-PRWeb/ -- Olive Fertility Centre is pleased to announce that Dr. Riki Dayan MD FRCSC has joined the Olive Fertility Victoria Team.
  • "We are delighted to welcome Dr. Dayan to Olive Fertility," says Olive co-director Dr. Niamh Talon.
  • "With her expertise in fertility, her dedication to education and her focus on whole person, patient-centred care, Dr. Dayan is an invaluable addition to the Olive Team."

National Women’s Law Center and Law Firm Emery Celli Brinckerhoff Abady Ward & Maazel, LLP Announce Settlement of Class Action Lawsuit Against Aetna Over LGBTQ+ Fertility Coverage

Retrieved on: 
金曜日, 5月 3, 2024
Class Action Lawsuit, Professional Services, Legal, Policy, Insemination, Infertility, Health, Male, Insurance, Fertility, Parent, Gender identity, Female, IVF, District court, Reproductive medicine, Society, Reproductive rights, Affordable Care Act, Health insurance

v. Aetna , filed in September 2021, the plaintiffs challenged Aetna’s definition of infertility, alleging it led to unequal insurance coverage treatment for LGBTQ+ couples.

Key Points: 
  • v. Aetna , filed in September 2021, the plaintiffs challenged Aetna’s definition of infertility, alleging it led to unequal insurance coverage treatment for LGBTQ+ couples.
  • Aetna will re-process eligible insurance claims to reimburse class members for their out-of-pocket artificial insemination cycles, up to the plan limits.
  • Aetna will also separately pay all the costs of the administrator and special master who will allocate the common fund.
  • If you believe you are in the class of individuals covered by this settlement, please visit this page or contact: 1-800-205-6861.

Second Opinion Expert Announces OC FERTILITY® + OC BIOGENIX® To Join Its Panel To Provide Expert Second Opinions.

Retrieved on: 
土曜日, 5月 4, 2024
Patient, PCOS, PGT, Infertility, Freezing, Anesthesiology, SOE, ICSI, Fertility, Genetic testing, IVF, Embryology, MPH, DANA, OC, IUI, FACOG, Semen analysis

DANA POINT, Calif., May 4, 2024 /PRNewswire-PRWeb/ -- SecondOpinionExpert, Inc. (SOE), a leading healthcare technology company, announced today that OC Fertility® + OC Biogenix® located in Newport Beach, Orange County, California will join SOE's expert panel to provide second opinions for fertility cases.

Key Points: 
  • DANA POINT, Calif., May 4, 2024 /PRNewswire-PRWeb/ -- SecondOpinionExpert, Inc. (SOE), a leading healthcare technology company, announced today that OC Fertility® + OC Biogenix® located in Newport Beach, Orange County, California will join SOE's expert panel to provide second opinions for fertility cases.
  • "We are honored to join the SOE panel to provide our expertise for challenging fertility cases and excited to leverage SOE's powerful second opinion platform as another way for us to help families," said Dr. Sharon Moayeri, founder and medical director of OC Fertility® + OC Biogenix®.
  • OC Fertility® + OC Biogenix® is a leading Southern California medical practice providing the best in fertility care and advanced laboratory services.
  • OC Fertility® + OC Biogenix®'s expert team features: Board-certified specialists, fellowship-trained in reproductive endocrinology, infertility, embryology, and anesthesiology, advanced public health education & advocacy and patient-centered, trauma-informed care.

Bridging Healthcare Gaps: The Wonder Woman Collective Unveils a New Vision for Women's Health

Retrieved on: 
金曜日, 5月 3, 2024
PCOS, Health equity, Urinary incontinence, Wonder, Infertility, Health, McKinsey & Company, Partnership, Human, Research, Pelvic floor dysfunction, Pelvic floor, Grammatical mood, Hypothyroidism, IVF, Entrepreneurship, Mental health, Patient, Work, Mother, Diagnosis, Migraine, Menopause, Quality of life, Nursing

With a shared commitment to innovation and excellence, this is the start of a foundation where future companies can join and redefine the standard of care in women's health. "With this initiative, we forge a new path in healthcare - one where comprehensive care, innovation, and patient-centricity are not just ideals, but realities. This is where the future of women's health begins." said Elizabeth Burstein, Co-Founder and CEO of Neura Health. Tina Keshani, Founder and CEO of Seven Starling adds "Women deserve specialized and tailored healthcare solutions to address their unique needs -- and no one company can do it all. "

Key Points: 
  • Five leading women's health companies, Paloma Health, Neura Health, LEVY Health, Seven Starling and Origin, have joined forces to announce The Wonder Woman Collective.
  • This strategic partnership addresses critical gaps in women's healthcare, focusing on improving healthcare outcomes, promoting health equity, reducing costs, and enhancing women's health.
  • "Addressing the Women's Health Gap is not just an option but a critical necessity.
  • "Through The Wonder Woman Collective, we are unifying diagnostic expertise and specialized care, enhancing the patient's journey and offering timely, comprehensive solutions," said Caroline Mitterdorfer, Co-Founder and CEO of LEVY Health.

Vitrolife AB (publ) acquires eFertility

Retrieved on: 
木曜日, 5月 2, 2024
EMR, EUR, Workflow, IVF, Rest, Automation, Acquisition, Hospital

GOTHENBURG, Sweden, May 2, 2024 /PRNewswire/ -- Vitrolife AB (publ) today signed an agreement to acquire 100% of the shares in eFertility (STB Zorg B.V.).

Key Points: 
  • GOTHENBURG, Sweden, May 2, 2024 /PRNewswire/ -- Vitrolife AB (publ) today signed an agreement to acquire 100% of the shares in eFertility (STB Zorg B.V.).
  • "The acquisition of eFertility represents a significant step in the Vitrolife Group's strategy to transform and digitalise the IVF patient journey.
  • Jan-Willem Broekman, CEO of eFertility, shared, "Joining the Vitrolife Group opens an exciting chapter for eFertility.
  • This disclosure contains information that Vitrolife AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014).

In Vitro Fertilization Market Projected to Reach US$ 1,940.8 Million Valuation by 2034: Future Market Insights, Inc.

Retrieved on: 
火曜日, 4月 30, 2024
Online, Merck Group, Nature, Area studies, Hope, MHealth, Hospital, Publication, News, Uday Chopra, Health care, ICSI, Research, Medication, Growth, IVF, Medical device, Social Problems, Cryopreservation, Fertilisation, Associate, Journal, FMI, Competitive intelligence, Pet industry

NEWARK, Del., April 30, 2024 /PRNewswire/ -- The in vitro fertilization market is on its way to perceive a surge in valuation, from US$ 1.50 billion in 2024 up to US$ 4.80 billion by 2034. FMI report indicates a healthy CAGR of 12.30% between 2024 and 2034, reckoning an influential IVF market growth.

Key Points: 
  • The breath analyzers market is poised for steady growth, with a projected CAGR of 4.9% from 2024 to 2034.
  • By 2034, the market is expected to reach a valuation of US$ 1,154.3 million, reflecting significant expansion.
  • The in vitro diagnostics market is poised for steady growth, with a projected CAGR of 4.8% during the forecast period.
  • Sales of donor egg IVF are projected to reach US$ 7,159.50 million by 2034, with a robust CAGR of 7.90% between 2024 and 2034.

Boston IVF Welcomes Dr. Josette Dawkins to its Springfield Fertility Center, Further Enhancing Access to Expert Reproductive Care in Western Massachusetts

Retrieved on: 
月曜日, 4月 29, 2024
University, Hysterosalpingography, PCOS, Suite, REI, MD, Fertility, Rochester Regional Health, Baystate, HSG, Obstetrics, IVF, Gynaecology, University of Massachusetts, Family, Medicine, Assistant, IUI, Medical director, Semen analysis, Nursing

SPRINGFIELD, Mass., April 29, 2024 /PRNewswire-PRWeb/ -- Boston IVF, one of the world's most experienced fertility treatment providers, which has assisted in over 150,000 babies born since 1986, is pleased to announce the addition of reproductive endocrinologist, Dr. Josette Dawkins, MD to its Springfield, MA fertility center and team.

Key Points: 
  • The addition of Dr. Josette Dawkins to Boston IVF and its fertility clinic in Springfield enriches the accessibility of timely reproductive care for individuals seeking to start a family.
  • She joins Boston IVF from Baystate Reproductive Medicine in Springfield, MA – where she served as its Medical Director.
  • "We are thrilled to extend a warm welcome to Dr. Josette Dawkins as she joins our esteemed Boston IVF team in Springfield, Massachusetts," expressed David Stern, CEO of Boston IVF.
  • "I am honored to become part of the respected team at Boston IVF," said Dr. Josette Dawkins.

Anti-Mullerian Hormone Test Market Projected to Reach $586.48 million by 2030 - Exclusive Report by 360iResearch

Retrieved on: 
土曜日, 4月 27, 2024
Use, Polycystic ovary syndrome, Ovarian reserve, PCOS, WHO, Hormone, Danaher Corporation, Primary ovarian insufficiency, Health, World Health Organization, Woman, Infertility, Anti-Müllerian hormone, Health care, AMH, Fertility, Table, Intelligence, IVF, Bio-Rad Laboratories, Privacy, Thermo Fisher Scientific, Diagnosis, POC, Growth, Birth control

Anti-mullerian hormone (AMH) tests are critical in assessing a woman's remaining egg count, potential fertility, and the health of her ovaries.

Key Points: 
  • Anti-mullerian hormone (AMH) tests are critical in assessing a woman's remaining egg count, potential fertility, and the health of her ovaries.
  • A key tool in identifying PCOS is the Anti-Müllerian hormone (AMH) test, which measures the levels of AMH produced by ovarian follicles.
  • We proudly unveil ThinkMi, a cutting-edge AI product designed to transform how businesses interact with the Anti-Mullerian Hormone Test Market.
  • "Dive into the Anti-Mullerian Hormone Test Market Landscape: Explore 195 Pages of Insights, 368 Tables, and 24 Figures"